140
Participants
Start Date
February 8, 2023
Primary Completion Date
September 30, 2026
Study Completion Date
October 31, 2026
Tirzepatide
Administered SC
Placebo
Administered SC
Klinik Landstraße, Vienna
Zentrum für klinische Studien Dr Hanusch Gmbh, Vienna
Klinik Hietzing, Vienna
Aarhus Universitetshospital, Skejby, Aarhus
Instituto Nacional de Cardiologia Ignacio Chavez, México
American Health Network of Indiana, LLC - Avon, Avon
American Health Network of Indiana, LLC - Greenfield, Greenfield
Indiana University Health University Hospital, Indianapolis
American Health Network of Indiana, LLC - Muncie, Muncie
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Investigación Nefrológica, Cuernavaca
University of Colorado Anschutz Medical Campus, Aurora
Kidney Associates of Colorado, Denver
Valley Clinical Trials, Inc., Northridge
University of Washington Medical Center - Montlake, Seattle
Providence Medical Research Center - Spokane, Spokane
LMC Clinical Research Inc. (Barrie), Barrie
LMC Clinical Research Inc. (Thornhill), Concord
Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T, Sherbrooke
Toronto General Hospital, Toronto
Fadia El Boreky Medicine, Waterloo
Centro de Investigación y Gastroenterología, Cuauhtémoc
Health Pharma Professional Research S.A. de C.V:, Mexico City
Grupo Medico Camino Sc, Mexico City
Caimed Investigacion En Salud S.A. de C.V., Mexico City
Ziekenhuisgroep Twente, locatie Almelo, Almelo
Amsterdam UMC, locatie VUmc, Amsterdam
Eli Lilly and Company
INDUSTRY